



Eurofins to enter the clinical diagnostics market in Brazil with the acquisition of Pasteur Group

21 December 2017

Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces that it has acquired Pasteur Group ("Pasteur"), a leading player in clinical diagnostics in greater area of Santos, Sao Paulo state.

Pasteur is located in the seaside of Sao Paulo state, where the largest port in Brazil and several important industries are located. As the leading clinical diagnostics testing group in the seaside of Sao Paulo, Pasteur expects to generate revenues in excess of BRL 25m in 2017. The company employs 190 staff.

Pasteur provides Eurofins an entry into the dynamic and growing clinical diagnostics market in the most populous Latin American country. This represents a new business line for Eurofins in Latin America, and provides a platform with significant organic and inorganic growth potential.

Comment from **Dr. Gilles Martin**, Eurofins CEO: "We are extremely pleased to welcome Pasteur to the Eurofins Group. Pasteur strengthens Eurofins' offer and footprint in the attractive clinical diagnostics testing market in Latin America. In return, Pasteur will gain access to the full range of services, companies and knowledge of the Eurofins Group, which should strengthen their analytical portfolio for the benefit of the patients and medical practitioners it serves. This transaction is another demonstration of Eurofins' commitment to expand its global network of analytical services laboratories across all geographical regions where it anticipates significant growth."

For more information, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes "Eurofins" or "the Group") believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agrosience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities

around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.